Cargando…

Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk

ABSTRACT: Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breast carcinoma classifications is based on its molecular aspects and subdivides breast cancer into five major groups based on the expression of certain genes. In this study, we evaluated which...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Solange Torchia, Stiepcich, Monica Maria, Fregnani, José Humberto, Nonogaki, Sueli, Rocha, Rafael, Soares, Fernando Augusto
Formato: Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093790/
https://www.ncbi.nlm.nih.gov/pubmed/21655754
http://dx.doi.org/10.1590/S1807-59322011000400014
_version_ 1782203498133192704
author Carvalho, Solange Torchia
Stiepcich, Monica Maria
Fregnani, José Humberto
Nonogaki, Sueli
Rocha, Rafael
Soares, Fernando Augusto
author_facet Carvalho, Solange Torchia
Stiepcich, Monica Maria
Fregnani, José Humberto
Nonogaki, Sueli
Rocha, Rafael
Soares, Fernando Augusto
author_sort Carvalho, Solange Torchia
collection PubMed
description ABSTRACT: Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breast carcinoma classifications is based on its molecular aspects and subdivides breast cancer into five major groups based on the expression of certain genes. In this study, we evaluated which factors are important in determining a prognosis after 5 years of follow-up for patients with clinical stage IIA breast tumors. We took into consideration the different phenotypes (luminal A luminal B HER-2 overexpression, basal and triple-negative), various epithelial-mesenchymal (EMT) molecular markers and adhesion molecules (E-cadherin, P-cadherin, N-cadherin, vimentin, twist snail and slug) and NOS-2, in addition to clinical and demographic data, tumor characteristics and treatment types. METHODS: The study population consisted of 82 patients with breast cancer. We analyzed eight molecular markers by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with ten years of follow-up, and we classified each tumor according to its estrogen receptor, progesterone receptor and HER-2 expression. We then placed the tumor into one of the above categories. RESULTS: The presence of several clinical and demographic factors, various histopathologies, treatment forms and several immunohistochemical markers were not associated with a worse prognosis for group IIA patients. The factors that were associated with a mortality risk were the triple-negative (odds ratio (OR) = 11.8, 95% confident interval (CI) = 2.0-70.3, P = 0.007) and basal (OR = 18.4, 95% CI = 1.8-184.7, P = 0.013) phenotypic patterns. CONCLUSIONS: The EMT markers and NOS-2 were not mortality risk factors. Basal and triple-negative phenotypic patterns were related to a higher mortality risk in patients with stage IIA tumors.
format Text
id pubmed-3093790
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-30937902011-05-17 Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk Carvalho, Solange Torchia Stiepcich, Monica Maria Fregnani, José Humberto Nonogaki, Sueli Rocha, Rafael Soares, Fernando Augusto Clinics (Sao Paulo) Clinical Science ABSTRACT: Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breast carcinoma classifications is based on its molecular aspects and subdivides breast cancer into five major groups based on the expression of certain genes. In this study, we evaluated which factors are important in determining a prognosis after 5 years of follow-up for patients with clinical stage IIA breast tumors. We took into consideration the different phenotypes (luminal A luminal B HER-2 overexpression, basal and triple-negative), various epithelial-mesenchymal (EMT) molecular markers and adhesion molecules (E-cadherin, P-cadherin, N-cadherin, vimentin, twist snail and slug) and NOS-2, in addition to clinical and demographic data, tumor characteristics and treatment types. METHODS: The study population consisted of 82 patients with breast cancer. We analyzed eight molecular markers by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with ten years of follow-up, and we classified each tumor according to its estrogen receptor, progesterone receptor and HER-2 expression. We then placed the tumor into one of the above categories. RESULTS: The presence of several clinical and demographic factors, various histopathologies, treatment forms and several immunohistochemical markers were not associated with a worse prognosis for group IIA patients. The factors that were associated with a mortality risk were the triple-negative (odds ratio (OR) = 11.8, 95% confident interval (CI) = 2.0-70.3, P = 0.007) and basal (OR = 18.4, 95% CI = 1.8-184.7, P = 0.013) phenotypic patterns. CONCLUSIONS: The EMT markers and NOS-2 were not mortality risk factors. Basal and triple-negative phenotypic patterns were related to a higher mortality risk in patients with stage IIA tumors. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2011-04 /pmc/articles/PMC3093790/ /pubmed/21655754 http://dx.doi.org/10.1590/S1807-59322011000400014 Text en Copyright © 2011 Hospital das Clínicas da FMUSP http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
Carvalho, Solange Torchia
Stiepcich, Monica Maria
Fregnani, José Humberto
Nonogaki, Sueli
Rocha, Rafael
Soares, Fernando Augusto
Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title_full Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title_fullStr Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title_full_unstemmed Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title_short Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk
title_sort evaluation of prognostic factors in stage iia breast tumors and their correlation with mortality risk
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093790/
https://www.ncbi.nlm.nih.gov/pubmed/21655754
http://dx.doi.org/10.1590/S1807-59322011000400014
work_keys_str_mv AT carvalhosolangetorchia evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk
AT stiepcichmonicamaria evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk
AT fregnanijosehumberto evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk
AT nonogakisueli evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk
AT rocharafael evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk
AT soaresfernandoaugusto evaluationofprognosticfactorsinstageiiabreasttumorsandtheircorrelationwithmortalityrisk